Emyria's drug registration model

EMD-003 Snapshot

ASX:EMD

myriad data.
individual care.

Disclaimer and notices

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Presentation release authorised by **Michael Winlo, CEO and Managing Director**



Emyria creates registered treatments for large, under-served populations using our proprietary clinical evidence

“Emyria owns clinics, cares for patients, invests in technology, generates data, creates evidence and develops programs to accelerate the registration of new treatments, including our own.”

Dr Michael Winlo, MD and CEO

Emyria's platform



Emyria's platform

Emyria Care

- **7 sites** around Australia
- **GCP-trained** clinical team
- **3,500 patients** and growing
- Patients aged **2 - 96years**
- Over **40 clinical indications**

Emyria Data

- **2.6M** data points
- **Validated** assessments
- Source of **IP**
- Unique **dose response** insights
- More than **100 products**

Emyria's current drug development programs



EMD-003

Targeting **mental health**

- *CBD medicine*
- *Entering clinical outcomes studies*
- *Seeking Schedule 3 registration*

EMD-004

Targeting **irritable bowel syndrome**

- *Real-world studies underway*



EMD-003

A strategic partnership with CANN GROUP LIMITED to accelerate the registration of a Schedule 3, (over-the-counter), CBD medicine

"Our first drug registration program brings together Emyria's unique insights on what is working in which patients with a highly differentiated CBD dose form that we already have substantive real-world data on."

Dr Michael Winlo, MD and CEO

EMD-003: Target indication
Unmet needs in mental health



Global unmet need

Emyria Data has unique insights

Major growing health concern

Psychological distress is growing in incidence

Affects 20.1% of all Australians

There has been a 13% rise in mental health conditions in the last decade

Need for new treatments

There is a growing interest for readily available, registered treatments with fewer:

- Adverse events
- Treatment costs
- Withdrawal symptoms
- Overdose risks

Affects Emyria patients

>60% of Emyria patients have Mild to Severe anxiety, depression and / or stress

>10% of Emyria patients have primary mental health concern

Real-world data already gathered on efficacy and safety of target dose form

Sources: https://www1.racgp.org.au/newsgp/clinical/mental-health-issues-increasing-among-australians + https://pubmed.ncbi.nlm.nih.gov/20051569/4 + https://www.who.int/health-topics/mental-health#tab=tab_2
https://www.aihw.gov.au/reports/mental-health-services/mental-health-services-in-australia/report-contents/mental-health-related-prescriptions/prescriptions

EMD-003: Program summary

Partnership accelerates registration pathway



EMD-003: Unique success factors in place

Strategic partnership accelerates path to S3 registration

emyria

Real-world data on safety & efficacy at target dose

- Longitudinal clinical data on over 3,500 patients and growing
- Over 400 prescriptions already written for target dose form

IP on "method of use"

- Unique insights support growing patent portfolio
- Emyria patents cover indication and dose range

Streamlined access to patients + clinical trial infrastructure

- 7 locations in Australia
- All GPs, GCP-trained
- Already running a clinical-trial-grade data capture platform

Protocols developed

- Clinical outcomes trials developed using Emyria Data insights and expertise of team

Regulatory strategy

- Engaged experienced regulatory consultant with prior S3 successes

Experienced drug development team

- Emyria team has overseen over 100 clinical trials and 25 drug approvals

Cann Group

Phase 1 & Stability data

- Phase 1 complete for target dose
- > 30+ months stability data

Unique, dose form protected by IP

- Covers use of novel delivery technology (Gelpell)

Large scale, GMP manufacturing

- Factory in Europe, transferring technology to Australia

This partnership greatly accelerates Emyria's EMD-003 drug development program by combining Emyria's unique clinical data and drug development expertise with Cann Group's best-in-class CBD delivery technology.

Cann Group's CBD has already completed robust stability testing as well as Phase 1 clinical trials as required by the TGA. This allows us to move straight to pivotal clinical outcomes trials saving significant time and money.

Dr Michael Winlo, MD and CEO

EMD-003: Milestones in year ahead

Value drivers next 12 months

Commence pivotal registration clinical trials

- Contingent on successful ethics committee review
- *Expected May/ June 2021*

Complete trial and commence analysis

- Contingent on recruitment success
- *Expected 4-8 months after commencement*

Prepare product dossier and submit to TGA for registration

- Preparation of full product dossier and clinical evidence package for evaluation
- *Expected 6-8 months after submission*

Obtain Schedule 3 registration

- Entry on Australian Register of Therapeutic Goods (ARTG) as a Schedule 3 medication

Finalise commercialisation agreements + commence sales

- Finalise commercialisation models
- Sales as over-the-counter, Schedule 3 medicine

Commence international registration activities

- Initiate activities to pursue global registrations

EMD-003: Proposed patient channel
A registered, over-the-counter, Schedule 3 medicine



FreshLeaf estimates that the pharmacist only CBD market in Australia will grow to $250m in product sales at market maturity, capturing around 2 million consumers[12].

Today, almost 1 in 4 medicinal cannabis patients take a CBD product at a daily dose below 150mg, spending an average of $8.02 per day[13].

FreshLeaf expects that this patient cohort will migrate to the pharmacy channel once low-dose CBD products become available over the counter meaning that the first product/s to hit the S3 market will take the lion's share of this group – around 10,000 patients spending almost ~$29M a year.

Current 'Special Access Scheme' Path



Potential Schedule 3 Path

If a low-dose CBD product can be successfully registered



$ Potential out-of-pocket expenses for patients

Sources: https://www.tga.gov.au/form/special-access-scheme
https://www.tga.gov.au/media-release/over-counter-access-low-dose-cannabidiol



Drug registration changes patient access

“Achieving formal drug registration demonstrates a product’s quality, safety and efficacy, makes a medicine mainstream and can improve patients’ access.”

Dr Michael Winlo, MD and CEO

Medicinal cannabis vs registered prescriptions
(via select drug groupings in Australia over 12 months)



Sources: https://www.pbs.gov.au/info/browse/statistics (data from 01 Jul 2018 to 30 Jun 2019
https://www.tga.gov.au/medicinal-cannabis-role-tga (data from 01 Nov 2019 to 31 Oct 2020) + Freshleaf Analytics, H1, 2021

Medicinal cannabis access in Australia

190 medicinal cannabis products available in Australia - most “unregistered”

1

Most medicinal cannabis products in Australia are “*unregistered*” and only available only via:

- Special Access Schemes
- Authorised Prescriber programs or;
- Clinical trials

Only 1 registered product is **available via prescription** [Epidyolex - GW Pharma] for **rare forms of epilepsy** with an estimated prevalence of 1 in 20k-40k

GW Pharma spent an estimated $560M on R&D between 2017 & 2020

Sources: https://www.tga.gov.au/australian-register-therapeutic-goods + Freshleaf Analytics, H1 2021 Report + https://mjbizdaily.com/gw-pharmaceuticals-sale-might-spur-pharma-cannabis-deal-making/

Recent deals | Jazz acquires GW Pharma ($7.2B USD)

***

Jazz Pharmaceuticals®

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

February 3, 2021

Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a potential near-term blockbuster

Enhanced product diversification of combined company expected to provide accelerated double-digit revenue growth

Anticipated to be accretive in first full year of combined operations and substantially accretive thereafter

Conference call today at 8:30 AM ET

DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021.

Upon close of the transaction, the combined company will be a leader in neuroscience with a global commercial and operational footprint well positioned to maximize the value of its diversified portfolio.

***

Emyria recently appointed Dr Karen Smith, Ex-Chief Medical Officer and Global Head of Research & Development at Jazz Pharmaceuticals to Chair Emyria's Strategic Advisory (See ASX Announcement 22 February 2021)



Emyria’s growing drug registration pipeline

Given our unique assets and the high-quality data we generate during care, the Emyria platform can generate multiple, independent drug development programs for new and emerging treatments.”

Dr Michael Winlo, MD and CEO

Emyria's pipeline targets large, under-served markets



+40 other indications

Cannabinoid | Psychedelic therapy | In planning | Where we are now

** Under Australia's Therapeutic Goods Administration (TGA), psychedelic medications such as psilocybin and MDMA are currently Schedule 9 of the Uniform Scheduling of Medicines and Poisons (which deals with Prohibited Substances). They are only available via approved research trials that include oversight by an institutional research ethics committee and careful monitoring and reporting of efficacy and safety outcomes. This work is with partner Mind Medicine Australia.*



Emyria’s experienced drug development team

“Our team has overseen more than 100 clinical trials and multiple drug registrations including with the FDA.”

Dr Michael Winlo, MD and CEO

Board with deep clinical and commercial expertise

Key Person	Role	
	**Dr Stewart Washer** **Chairman & Founder**	**Cynata** (ASX:CYP) – stem cells **Orthocell** (ASX:OCC) – regenerative medicine **Botanix** (ASX:BOT) – CBD (synthetic)
	**Dr Michael Winlo** **Managing Director**	**Medical doctor** Director at **Linear Clinical** Health Lead at **Palantir** MBA from **Stanford University**
	**Dr Alistair Vickery** **Medical Director**	Specialist **general practitioner** Chair of **Black Swan Health**, - mental health Associate **Professor of Primary Health Care**
	**Matt Callahan** **NED & Founder**	Founder **Botanix** (ASX:BOT), Founder **Orthocell** (ASX:OCC) 4 products through **FDA approval**. More than 20 years' **legal and IP experience**
	**Professor Sir John Tooke** **Independent NED**	**Knighted** in the UK for Services to Medicine Senior Independent Director, **BUPA Chile** Head of Medical Sciences at **UCL** Review board of **Google DeepMind** Immediate past **President Academy of Medical Sciences**

Recently appointed Key Advisors

Key Person	Role	
	**Dr Karen Smith** M.D., Ph.D., M.B.A., L.L.M **Chair of Strategic Advisory**	• Experienced **pharmaceutical expert** • **Multiple Directorships** with innovative pharmaceutical companies • Ex-**Chief Medical Officer and Global Head of R&D at Jazz Pharmaceuticals** • Overseen more than **100 clinical trials and 20 regulatory approvals** • Appointment boosts Emyria's global clinical trial and regulatory approval expertise to accelerate drug registration • Appointment to support innovation across Emyria's drug development programs, clinical studies and evidence-generating care model
	**Dr Richard Magtengaard** **Consultant Psychiatrist**	• **Consultant Psychiatrist** and retired **Naval Officer** • Current **Director of Military Trauma Recovery** Programme for sustained physical and psychological traumas • active member of the **Australasian Military Medical Association** (AMMA) and has developed lasting affiliations with **ADF Joint Health Command** (JHC), **Returned Services League** WA (RSLWA), St John Ambulance (SJA), West Australian Police (WAPOL), Department of Fire and Emergency Services (DFES), Australian Federal Police (AFP) and numerous other Ex-Service Organisations (ESOs) • Appointment boosts Emyria's clinical expertise in mental health care



Emyria is poised for growth

Within 12 months we have...



- Over **3,500 patients** with unmet needs
- **7 clinic locations** Emerald Clinics
- **Specialist advisors** & **GCP-trained GPs**
- **Over 400 referring clinicians**

- Launched **2 drug development programs**:
- **EMD-003** (schedule 3 medicine for psychological distress)
- **EMD-004** (cannabinoid for IBS)



- Over **2.6M validated data points**
- $1M of data deals inc. with **Canopy Growth Corp**

- Multiple **PhD-trained data analysts**
- Informing **strategic trial design**
- **Patents** already filed

- **TGA registered** remote monitoring systems
- **Major WA Health grant award** ($880k) for remote monitoring of vital signs and mental health



- **UK** clinical partner - Sapphire Medical (London)
- **USA** strategic partner - Mt Sinai (New York)
- Partnership with Mind Medicine **Australia** to develop psychedelic-assisted therapy model

Emyria positioned to rapidly & repeatedly develop new treatments



Emyria's Digital Health Platform

- Obtain further **TGA registrations**
- Incorporate best-in-class vital sign technology to develop **digital biomarkers**
- Work with **partners (eg Mt Sinai)** to extend platform capability

emyria

myriad data.
individual care.

Contact Information

Michael Winlo: mwinlo@emyria.com

Investors: investors@emyria.com

Media: media@emyria.com

General: info@emyria.com

ASX:EMD